Biotech · Public company · Redwood City, CA, US

MapLight Therapeutics, Inc.

Ticker MPLT · SEC CIK 0001770069

Track this companyFree. Adds MapLight Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials64 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

ML-004 (IR)/(ER) tabletPhase 2 · Autism Spectrum DisorderClinicalTrials.gov · fetched Nov 12, 2026
ML-007C-MAPhase 2 · Psychosis Associated With Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
ML-007C-MAPhase 2 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
ML-007C-MA BIDPhase 2 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
ML-007C-MA QDPhase 2 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026

A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaPHASE2 · RECRUITING · started Mar 31, 2026ClinicalTrials.gov NCT07459647 · fetched Nov 12, 2026
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisPHASE2 · ENROLLING_BY_INVITATION · started Mar 25, 2026ClinicalTrials.gov NCT07459660 · fetched Nov 12, 2026
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPHASE2 · RECRUITING · started Aug 15, 2025ClinicalTrials.gov NCT06887192 · fetched Nov 12, 2026
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaPHASE2 · COMPLETED · started Jun 27, 2025ClinicalTrials.gov NCT07038876 · fetched Nov 12, 2026
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 1, 2023ClinicalTrials.gov NCT05889273 · fetched Nov 12, 2026
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)PHASE2 · COMPLETED · started Sep 13, 2022ClinicalTrials.gov NCT05081245 · fetched Nov 12, 2026